摘要 |
<p>The invention describes and claims the use of 1α-Vitamin D2 as a medicament in the treatment of osteoporosis. Active Vitamin D3 compounds are ineffective or minimally effective at dosage ranges which can be tolerated by the human. At dosage ranges which are required to effectively restore lost bone mass, active Vitamin D3 compounds present a serious amount of toxicity in the form of hypercalcemia and hypercalciuria. The inventors have found that 1α-Vitamin D2 which is equally as active as 1α-Vitamin D3 in stimulating intestinal calcium absorption can be safely administered at dosages above 3.0 νg/day without stimulating bone reabsorption.</p> |